Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pergolide as primary therapy for macroprolactinomas.

J J Orrego1, W F Chandler, A L Barkan

  • 1Department of Surgery, University of Michigan Medical Center and Department of Veterants Affairs Medical Center, Ann Arbor 48109, USA.

Pituitary
|January 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of pulsatile growth hormone (GH) secretion in the regulation of lipolysis in fasting humans.

Clinical diabetes and endocrinology·2022
Same author

Massive symptomatic subependymoma of the lateral ventricles: case report and review of the literature.

Neuroradiology·2005
Same author

Acromegalic arthropathy.

Pituitary·2002
Same author

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Lancet (London, England)·2001
Same author

Semiquantification of hypothalamic GH-releasing hormone output in women: evidence for sexual dimorphism in the mechanism of the somatopause.

The Journal of clinical endocrinology and metabolism·2001
Same author

Regulation of GH secretion in acromegaly: reproducibility of daily GH profiles and attenuated negative feedback by IGF-I.

The Journal of clinical endocrinology and metabolism·2001
Same journal

Clinician decision-making in non-functioning pituitary adenomas: an Australian and New Zealand interdisciplinary survey study.

Pituitary·2026
Same journal

Does persistent hyperprolactinemia contribute to bone loss independently of estrogen deficiency in postmenopausal women?

Pituitary·2026
Same journal

Gauze swabbing technique for safe dissection of pituitary tumors.

Pituitary·2026
Same journal

Postoperative changes in circulating brain injury biomarkers in relation to long-term fatigue and cognitive outcomes after surgery for nonfunctioning pituitary adenomas.

Pituitary·2026
Same journal

Pituitary metastasis as an endocrine-neuro-ophthalmologic emergency: clinical red flags and outcomes from a contemporary tertiary-center series.

Pituitary·2026
Same journal

GH responsiveness to corticotropin-releasing hormone identifies corticotroph-like somatotroph adenomas in acromegaly.

Pituitary·2026
See all related articles

Pergolide effectively treats macroprolactinomas in patients not concerned about pregnancy. This dopamine agonist significantly reduces prolactin levels and tumor volume, offering a safe and affordable first-line option.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Macroprolactinomas are pituitary tumors that overproduce prolactin.
  • Effective treatment is crucial for managing symptoms and preventing complications.

Purpose of the Study:

  • To evaluate pergolide therapy for de novo treatment of macroprolactinomas.
  • To assess pergolide's efficacy and safety in patients where pregnancy is not a concern.

Main Methods:

  • Prospective study of 22 patients with macroprolactinomas.
  • Administered pergolide daily, with doses ranging from 0.05 to 0.5 mg.
  • Monitored prolactin levels, tumor volume, and clinical symptoms.

Main Results:

  • Mean prolactin levels decreased by 88% after 12 months.

Related Experiment Videos

  • Tumor volume shrinkage of 25% or greater observed in 86% of patients.
  • Significant improvement in visual abnormalities and normalization of testosterone levels in men.

    • Conclusions:

    • Pergolide is a safe, inexpensive, and well-tolerated dopamine agonist for macroprolactinoma treatment.
    • It demonstrates significant efficacy in reducing prolactin levels and tumor size.
    • Pergolide shows potential as a first-line therapy for select macroprolactinoma patients.